Generic and biosimilar entry will offset revenues from 2023.
By Zachary McLellan, Analyst
23 April 2016
I am an oncology analyst at Datamonitor Healthcare based in the New York office. I joined Datamonitor in June 2015 while...
Read full bio
Beginning in 2023, the entry of cheaper generic and biosimilar drugs will offset the sales generated by branded therapies and decrease the overall revenue of the hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer market. Branded therapies predicted to face generic or biosimilar competition in at least one market over the course of the forecast include Afinitor (everolimus; Novartis), Avastin (bevacizumab; Genentech/Roche/Chugai), Faslodex, Halaven (eribulin mesylate; Eisai), Ibrance (palbociclib; Pfizer), and Ixempra (ixabepilone; R-Pharm/Otsuka). Datamonitor Healthcare predicts that large portions of patients will switch to the much cheaper generic and biosimilar products and sales in the HR+/HER2- breast cancer market will decrease by 9% from 2022–24 as a result.
HR+/HER2- breast cancer generic/biosimilar sales across the US, Japan, and five major EU markets ($m), 2015–24
|Source: Datamonitor Healthcare|
Datamonitor Healthcare surveyed 229 medical oncologists and mammary gland specialists across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to calculate the HR+/HER2- breast cancer treatment population and to gain an understanding of current and future prescribing patterns in HR+/HER2- breast cancer. Datamonitor Healthcare’s HR+/HER2- breast cancer forecast covers the expected impact of newly branded therapies on the HR+/HER2- market, as well as the potential impact of HR+/HER2- pipeline candidates and generic/biosimilar products.
Get your free demo today – simply fill out the form to the right.